Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ERIS LIFESCIENCES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ERIS LIFESCIENCES   ACTAVIS
EQUITY SHARE DATA
    ERIS LIFESCIENCES
Mar-23
ACTAVIS
Dec-18
ERIS LIFESCIENCES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs75016,126-   
Low Rs55110,818-   
Sales per share (Unadj.) Rs123.93,955.8-  
Earnings per share (Unadj.) Rs27.5-1,274.2-  
Cash flow per share (Unadj.) Rs36.1416.9-  
Dividends per share (Unadj.) Rs7.350-  
Avg Dividend yield %1.10-  
Book value per share (Unadj.) Rs161.316,315.7-  
Shares outstanding (eoy) m135.99332.60-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x5.23.4 154.1%   
Avg P/E ratio x23.6-10.6 -223.6%  
P/CF ratio (eoy) x18.032.3 55.7%  
Price / Book Value ratio x4.00.8 488.4%  
Dividend payout %26.70-   
Avg Mkt Cap Rs m88,4464,480,758 2.0%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m3,4620-   
Avg. sales/employee Rs Th077,851.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0-25,076.0-  
INCOME DATA
Net Sales Rs m16,8511,315,689 1.3%  
Other income Rs m11225,160 0.4%   
Total revenues Rs m16,9631,340,849 1.3%   
Gross profit Rs m5,36934,478 15.6%  
Depreciation Rs m1,171562,428 0.2%   
Interest Rs m26375,923 0.3%   
Profit before tax Rs m4,046-578,713 -0.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0147,595 0.0%   
Tax Rs m305-7,334 -4.2%   
Profit after tax Rs m3,742-423,784 -0.9%  
Gross profit margin %31.92.6 1,215.9%  
Effective tax rate %7.51.3 594.4%   
Net profit margin %22.2-32.2 -68.9%  
BALANCE SHEET DATA
Current assets Rs m8,427539,627 1.6%   
Current liabilities Rs m5,212477,372 1.1%   
Net working cap to sales %19.14.7 403.2%  
Current ratio x1.61.1 143.0%  
Inventory Days Days1520 76.2%  
Debtors Days Days6366 95.6%  
Net fixed assets Rs m26,287148,929 17.7%   
Share capital Rs m1360-   
"Free" reserves Rs m21,7960-   
Net worth Rs m21,9325,426,601 0.4%   
Long term debt Rs m6,4441,910,903 0.3%   
Total assets Rs m34,7138,483,012 0.4%  
Interest coverage x16.4-6.6 -247.0%   
Debt to equity ratio x0.30.4 83.4%  
Sales to assets ratio x0.50.2 313.0%   
Return on assets %11.5-4.1 -281.4%  
Return on equity %17.1-7.8 -218.5%  
Return on capital %15.2-4.8 -313.8%  
Exports to sales %00-   
Imports to sales %0.50-   
Net fx Rs m-5,3270-   
CASH FLOW
From Operations Rs m2,917470,046 0.6%  
From Investments Rs m-9,821258,229 -3.8%  
From Financial Activity Rs m6,880-806,740 -0.9%  
Net Cashflow Rs m52-78,073 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare ERIS LIFESCIENCES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ERIS LIFESCIENCES With: SUN PHARMA  PFIZER  KILITCH DRUGS  SAROJA PHARMA INDUSTRIES INDIA LTD.  SEQUENT SCIENTIFIC  



Today's Market

Sensex Today Trades Flat | Nifty Below 22,350 | Kotak Mahindra Bank Tanks 9% Sensex Today Trades Flat | Nifty Below 22,350 | Kotak Mahindra Bank Tanks 9%(10:30 am)

Asian stocks fell on Thursday as disappointing earnings forecasts from Facebook parent Meta Platforms hammered tech shares, while the yen's slump past 155 per dollar.